NASDAQ:BLPH - Bellerophon Therapeutics Stock Price, Forecast & News

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BLPH shares have increased by 95.5% and is now trading at $12.30. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bellerophon Therapeutics.

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, April 2nd 2020. View our earnings forecast for Bellerophon Therapeutics.

Bellerophon Therapeutics Inc (NASDAQ:BLPH) posted its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.20. View Bellerophon Therapeutics' earnings history.

Bellerophon Therapeutics's stock reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

2 equities research analysts have issued 1 year target prices for Bellerophon Therapeutics' shares. Their forecasts range from $30.00 to $30.00. On average, they expect Bellerophon Therapeutics' stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 143.9% from the stock's current price. View analysts' price targets for Bellerophon Therapeutics.

News headlines about BLPH stock have trended very negative recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bellerophon Therapeutics earned a media sentiment score of -3.7 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news aboutBellerophon Therapeutics.

Bellerophon Therapeutics saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 50,300 shares, a drop of 46.9% from the February 27th total of 94,800 shares. Based on an average trading volume of 57,700 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.5% of the company's shares are sold short. View Bellerophon Therapeutics' Current Options Chain.

Some companies that are related to Bellerophon Therapeutics include Evofem Biosciences (EVFM), Galera Therapeutics (GRTX), Syros Pharmaceuticals (SYRS), Stemline Therapeutics (STML), MannKind (MNKD), Gemphire Therapeutics (GEMP), Geron (GERN), AMAG Pharmaceuticals (AMAG), Aduro BioTech (ADRO), Lexicon Pharmaceuticals (LXRX), Mallinckrodt (MNK), XOMA (XOMA), OptiNose (OPTN), Selecta Biosciences (SELB) and NuCana (NCNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Opko Health (OPK), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Actinium Pharmaceuticals (ATNM), Aurinia Pharmaceuticals (AUPH), TrovaGene (TROV) and vTv Therapeutics (VTVT).

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BLPH stock can currently be purchased for approximately $12.30.

Bellerophon Therapeutics has a market capitalization of $56.36 million. The biotechnology company earns $2.81 million in net income (profit) each year or ($5.10) on an earnings per share basis. Bellerophon Therapeutics employs 17 workers across the globe. View additional information about Bellerophon Therapeutics.

The official website for Bellerophon Therapeutics is http://www.bellerophon.com/.

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]